"""
Question: 1101 

Evidence: Clinical validation of this version of the OLA-Simple was conducted on 60 plasma specimens from a cohort in Mexico selected by collaborators at CIENI/INER to include a high proportion of specimens with PDR. De-identified specimens from treatment-naive adults were blindly tested by OLA-Simple , and the results compared to results from MiSeq sequencing. GenBank accession numbers are MT044195-MT044237; MT070765-MT070781.

Rationale: The study describes a new validation using 60 Mexican plasma specimens with blinded OLA-Simple testing and comparison to MiSeq, and it provides new sequence depositions with GenBank accessions, indicating previously unpublished data.

Answer: Yes
"""

"""
Question: 1102 

Evidence: Deep sequencing by MiSeq (Illumina, San Diego, California, USA) on near-full genome HIV amplicons was performed at the CIENI/INER laboratory in Mexico City as previously described. GenBank accession numbers are MT044195-MT044237; MT070765-MT070781.

Rationale: The methods confirm that HIV genomes were sequenced by MiSeq and the paper lists GenBank accession numbers, demonstrating that HIV sequences are reported.

Answer: Yes
"""

"""
Question: 1103 

Evidence: Plasma specimens were extracted using the Qiagen QIAamp Viral RNA kit (Qiagen, Hilden, Germany) according to the manufacturer's instructions. Extracted RNA was reverse-transcribed in a rehydrated lyophilized reverse-transcription reaction. DNA standards containing plasmid mixtures with 0%, 10%, 25%, and 100% of MUT target (n = 5 each) were genotyped by OLA-Simple.

Rationale: The paper describes testing clinical plasma RNA and plasmid standards, with no mention of serial passage or culture-based in vitro passage experiments.

Answer: No
"""

"""
Question: 1104 

Evidence: OLA- Simple detects the presence of specific drug-resistance mutations in a PCR amplified HIV template with nearly 100% specificity conveyed by enzyme-mediated ligation of labeled genotype-specific oligonucleotide probes to a common capture probe at the site of the mutation. Amino acid mutations were queried against the Stanford HIV Drug Resistance Database.

Rationale: The study reports genotypic detection of mutations and database interpretation; there are no phenotypic susceptibility assays or IC50 measurements, so no novel in vitro susceptibility data are presented.

Answer: No
"""

"""
Question: 2101 

Evidence: GenBank accession numbers are MT044195-MT044237; MT070765-MT070781. De-identified specimens from treatment-naive adults were blindly tested by OLA-Simple , and the results compared to results from MiSeq sequencing.

Rationale: The text explicitly lists GenBank accession numbers corresponding to sequenced HIV samples from clinical specimens.

Answer: Yes
"""

"""
Question: 2102 

Evidence: GenBank accession numbers are MT044195-MT044237; MT070765-MT070781. De-identified specimens from treatment-naive adults were blindly tested by OLA-Simple , and the results compared to results from MiSeq sequencing.

Rationale: Because the accessions correspond to de-identified clinical specimens from treatment-naive adults rather than laboratory strains, they are not limited to laboratory isolates.

Answer: Yes
"""

"""
Question: 2103 

Evidence: GenBank accession numbers are MT044195-MT044237; MT070765-MT070781.

Rationale: The paper lists two contiguous accession ranges; these are the GenBank accession numbers reported.

Answer: MT044195–MT044237; MT070765–MT070781
"""

"""
Question: 2202 

Evidence: Genotyping data by OLA-Simple and MiSeq are available in Supplementary Table 2 (https://links.lww.com/QAD/B693). Percentage sensitivity and specificity at other diagnostic thresholds are shown in Supplementary Table 3 (https://links.lww.com/QAD/B693).

Rationale: The paper refers to a supplementary table containing per-specimen genotyping results by both methods, which implies mutation lists or calls at specific codons for individual samples.

Answer: Yes
"""

"""
Question: 2301 

Evidence: Near point-of-care, point-mutation test to detect drug resistance in HIV-1: a validation study in a Mexican cohort. Moreover, an OLA-Simple kit that detects the NRTI mutation M184V and NNRTI mutations K103N, Y181C, and G190A was clinically validated across multiple HIV-1 subtypes.

Rationale: The title and text specify HIV-1 as the species under study.

Answer: HIV-1
"""

"""
Question: 2302 

Evidence: To improve ligation efficiency in the Mexican cohort, where HIV subtype B accounts for nearly 99% of infections [14,22 – 24], we designed subtype B-specific probes. Assay optimization was performed using HIV subtype B plasmids mixtures containing 0, 10, 25, and 100% mutant for all codons tested.

Rationale: The sequenced cohort is from Mexico where nearly all infections are subtype B; the assay optimization also used subtype B, indicating the reported sequences are predominantly subtype B.

Answer: Subtype B (nearly all)
"""

"""
Question: 2303 

Evidence: Deep sequencing by MiSeq (Illumina, San Diego, California, USA) on near-full genome HIV amplicons was performed at the CIENI/INER laboratory in Mexico City as previously described. The alignment of 2412 Mexican HIV pol sequences showed considerable variability in the area of several OLA-Simple kit probes.

Rationale: The methods indicate near-full genome sequencing, and the analyses emphasize pol sequences for drug resistance evaluation.

Answer: Near-full genome sequences, with analyses focused on pol
"""

"""
Question: 2304 

Evidence: The alignment of 2412 Mexican HIV pol sequences showed considerable variability in the area of several OLA-Simple kit probes. Amino acid mutations were queried against the Stanford HIV Drug Resistance Database.

Rationale: The paper explicitly discusses pol sequence alignments and mutation analyses, indicating results from pol sequences were reported.

Answer: Yes
"""

"""
Question: 2401 

Evidence: A database containing HIVDR profiles from 2412 individuals initiating first-line ART in Mexico City genotyped by MiSeq was used to select 60 plasma specimens. Clinical validation of this version of the OLA-Simple was conducted on 60 plasma specimens from a cohort in Mexico.

Rationale: The sequences and specimens are from Mexico City, Mexico.

Answer: Mexico City, Mexico
"""

"""
Question: 2402 

Evidence: OLA-Simple probes designed to detect K65R, K103N/S, Y181C, M184V, and G190A across multiple subtypes were modified to include polymorphisms observed frequently in pol sequences from individuals initiating an NNRTI/NRTI regimen in Mexico City between September 2017 and March 2018.

Rationale: The timeframe for the sequenced samples used to inform probe design is explicitly stated.

Answer: September 2017 to March 2018
"""

"""
Question: 2502 

Evidence: Deep sequencing by MiSeq (Illumina, San Diego, California, USA) on near-full genome HIV amplicons was performed at the CIENI/INER laboratory in Mexico City as previously described. DNA libraries were prepared using Nextera XT DNA Sample Preparation kit and Nextera XT Index Kits (Illumina), according to the manufacturer's protocol.

Rationale: The sequencing platform was Illumina MiSeq (NGS), not Sanger sequencing.

Answer: No
"""

"""
Question: 2503 

Evidence: Deep sequencing by MiSeq (Illumina, San Diego, California, USA) on near-full genome HIV amplicons was performed at the CIENI/INER laboratory in Mexico City as previously described. Fastq files from the sequencing runs were aligned and assessed for HIVDR frequencies using HyDRA.

Rationale: Illumina MiSeq is an NGS technology.

Answer: Yes
"""

"""
Question: 2504 

Evidence: Deep sequencing by MiSeq (Illumina, San Diego, California, USA) on near-full genome HIV amplicons was performed. DNA libraries were prepared using Nextera XT DNA Sample Preparation kit and Nextera XT Index Kits (Illumina), according to the manufacturer's protocol.

Rationale: The sequencing was performed on PCR amplicons with library preparation for NGS; no molecular cloning of samples was described.

Answer: No
"""

"""
Question: 2505 

Evidence: Deep sequencing by MiSeq (Illumina, San Diego, California, USA) on near-full genome HIV amplicons was performed. Fastq files from the sequencing runs were aligned and assessed for HIVDR frequencies using HyDRA.

Rationale: The study used bulk deep sequencing of amplicons rather than single-genome sequencing.

Answer: No
"""

"""
Question: 2506 

Evidence: DNA libraries were prepared using Nextera XT DNA Sample Preparation kit and Nextera XT Index Kits (Illumina), according to the manufacturer's protocol. Deep sequencing by MiSeq on near-full genome HIV amplicons was performed.

Rationale: The protocol involves PCR amplicons and library prep for NGS without molecular cloning.

Answer: No
"""

"""
Question: 2601 

Evidence: Clinical validation of this version of the OLA-Simple was conducted on 60 plasma specimens from a cohort in Mexico. Deep sequencing by MiSeq (Illumina, San Diego, California, USA) on near-full genome HIV amplicons was performed at the CIENI/INER laboratory in Mexico City as previously described.

Rationale: The specimens are explicitly described as plasma, and MiSeq sequencing results were used.

Answer: Yes
"""

"""
Question: 2602 

Evidence: Clinical validation of this version of the OLA-Simple was conducted on 60 plasma specimens from a cohort in Mexico. Plasma specimens were extracted using the Qiagen QIAamp Viral RNA kit (Qiagen, Hilden, Germany) according to the manufacturer's instructions.

Rationale: The study specifically used plasma; PBMC sequencing was not mentioned.

Answer: No
"""

"""
Question: 2603 

Evidence: A database containing HIVDR profiles from 2412 individuals initiating first-line ART in Mexico City genotyped by MiSeq was used to select 60 plasma specimens. De-identified specimens from treatment-naive adults were blindly tested by OLA-Simple , and the results compared to results from MiSeq sequencing.

Rationale: The 60 plasma specimens had MiSeq genotypes available and were the basis for comparisons.

Answer: 60
"""

"""
Question: 2604 

Evidence: Clinical validation of this version of the OLA-Simple was conducted on 60 plasma specimens from a cohort in Mexico. Plasma specimens were extracted using the Qiagen QIAamp Viral RNA kit (Qiagen, Hilden, Germany) according to the manufacturer's instructions.

Rationale: Only plasma specimens are described; PBMC sequencing is not reported.

Answer: 0
"""

"""
Question: 2605 

Evidence: Across these specimens, 98.3% (59/60) amplified by reverse transcription polymerase chain reaction (RT-PCR) (median viral load: 103 586, range 176--10 000 000 copies/ml). The one specimen that failed amplification had a plasma HIV RNA load of 176 copies/ml.

Rationale: The presence of plasma HIV RNA with measured viral loads indicates active replication in the individuals sampled.

Answer: Yes
"""

"""
Question: 2606 

Evidence: Plasma specimens were extracted using the Qiagen QIAamp Viral RNA kit (Qiagen, Hilden, Germany) according to the manufacturer's instructions. Extracted RNA was reverse-transcribed in a rehydrated lyophilized reverse-transcription reaction.

Rationale: Sequencing and testing were performed on plasma RNA, not on proviral DNA reservoirs.

Answer: No
"""

"""
Question: 2701 

Evidence: De-identified specimens from treatment-naive adults were blindly tested by OLA-Simple , and the results compared to results from MiSeq sequencing. Clinical validation of this version of the OLA-Simple was conducted on 60 plasma specimens from a cohort in Mexico.

Rationale: The subjects are explicitly described as adults; there is no indication of infants or children as sample sources.

Answer: No
"""

"""
Question: 2702 

Evidence: All participants provided written informed consent before blood sample donation for HIV genotyping. The study was approved by the Institutional Review Board of the National Institute of Respiratory Diseases -- institution where HIV sequencing was performed (Project code: E02--17).

Rationale: The paper describes consent and IRB approval but does not indicate enrollment in any clinical trial, so this cannot be determined from the text.

Answer: NA
"""

"""
Question: 2703 

Evidence: All participants provided written informed consent before blood sample donation for HIV genotyping. The study was approved by the Institutional Review Board of the National Institute of Respiratory Diseases -- institution where HIV sequencing was performed (Project code: E02--17).

Rationale: There is no statement that all individuals were in a clinical trial; this information is not provided.

Answer: NA
"""

"""
Question: 3101 

Evidence: A database containing HIVDR profiles from 2412 individuals initiating first-line ART in Mexico City genotyped by MiSeq was used to select 60 plasma specimens. De-identified specimens from treatment-naive adults were blindly tested by OLA-Simple , and the results compared to results from MiSeq sequencing.

Rationale: The number of individuals whose samples were selected for sequencing comparison in this study is 60.

Answer: 60
"""

"""
Question: 3102 

Evidence: A database containing HIVDR profiles from 2412 individuals initiating first-line ART in Mexico City genotyped by MiSeq was used to select 60 plasma specimens. De-identified specimens from treatment-naive adults were blindly tested by OLA-Simple , and the results compared to results from MiSeq sequencing.

Rationale: The 60 individuals were selected from those already genotyped by MiSeq, indicating all had sequencing data.

Answer: Yes
"""

"""
Question: 4101 

Evidence: De-identified specimens from treatment-naive adults were blindly tested by OLA-Simple , and the results compared to results from MiSeq sequencing. A database containing HIVDR profiles from 2412 individuals initiating first-line ART in Mexico City genotyped by MiSeq was used to select 60 plasma specimens.

Rationale: The individuals were treatment-naive at sampling, so sequences represent ART-naive individuals.

Answer: Yes
"""

"""
Question: 4102 

Evidence: De-identified specimens from treatment-naive adults were blindly tested by OLA-Simple , and the results compared to results from MiSeq sequencing. 

Rationale: Because the individuals were treatment-naive, the study does not report sequences from ARV-experienced persons.

Answer: No
"""

"""
Question: 4103 

Evidence: De-identified specimens from treatment-naive adults were blindly tested by OLA-Simple , and the results compared to results from MiSeq sequencing.

Rationale: Only ART-naive individuals are described, not a mix of naive and experienced.

Answer: No
"""

"""
Question: 4104 

Evidence: A database containing HIVDR profiles from 2412 individuals initiating first-line ART in Mexico City genotyped by MiSeq was used to select 60 plasma specimens. De-identified specimens from treatment-naive adults were blindly tested by OLA-Simple , and the results compared to results from MiSeq sequencing.

Rationale: All 60 selected specimens were from ART-naive individuals initiating first-line ART.

Answer: 60
"""

"""
Question: 4105 

Evidence: De-identified specimens from treatment-naive adults were blindly tested by OLA-Simple. 

Rationale: The paper states only that participants were treatment-naive; it does not provide detailed ART histories beyond that for all individuals.

Answer: No
"""

"""
Question: 4201 

Evidence: HIV drug resistance (HIVDR) to antiretroviral therapy (ART) has increased globally, with a prevalence of pretreatment HIVDR (PDR) of 5 – 20% and 50 – 90% in people failing ART [1]. 

Rationale: The paper reports PDR prevalence, not specifically the prevalence of transmitted HIV drug resistance; therefore, it does not report TDR prevalence.

Answer: No
"""

"""
Question: 4202 

Evidence: HIV drug resistance (HIVDR) to antiretroviral therapy (ART) has increased globally, with a prevalence of pretreatment HIVDR (PDR) of 5 – 20% and 50 – 90% in people failing ART [1].

Rationale: The introduction explicitly states the prevalence of pretreatment HIV drug resistance.

Answer: Yes
"""

"""
Question: 4301 

Evidence: De-identified specimens from treatment-naive adults were blindly tested by OLA-Simple. A database containing HIVDR profiles from 2412 individuals initiating first-line ART in Mexico City genotyped by MiSeq was used to select 60 plasma specimens.

Rationale: The individuals were treatment-naive at sampling; thus, no drug classes had been received at that time.

Answer: NA
"""

"""
Question: 4302 

Evidence: De-identified specimens from treatment-naive adults were blindly tested by OLA-Simple. In response to the high prevalence of PDR to NNRTI, the WHO recommends countries with more than 10% PDR to start all people living with HIV on a preferred first-line regimen containing dolutegravir/NRTIs.

Rationale: Although integrase inhibitors are discussed in context, the sampled individuals were treatment-naive and not reported to have received INSTIs.

Answer: No
"""

"""
Question: 4303 

Evidence: De-identified specimens from treatment-naive adults were blindly tested by OLA-Simple. 

Rationale: No individuals are reported to have received protease inhibitors; participants were ART-naive.

Answer: No
"""

"""
Question: 4304 

Evidence: De-identified specimens from treatment-naive adults were blindly tested by OLA-Simple. 

Rationale: Since participants were ART-naive, whether they received the same ART is not applicable.

Answer: NA
"""

"""
Question: 4305 

Evidence: De-identified specimens from treatment-naive adults were blindly tested by OLA-Simple. A database containing HIVDR profiles from 2412 individuals initiating first-line ART in Mexico City genotyped by MiSeq was used to select 60 plasma specimens.

Rationale: As treatment-naive, they had not received INSTIs.

Answer: Yes
"""

"""
Question: 4403 

Evidence: De-identified specimens from treatment-naive adults were blindly tested by OLA-Simple.

Rationale: Being ART-naive, none had received more than one regimen.

Answer: 0
"""

"""
Question: 4404 

Evidence: De-identified specimens from treatment-naive adults were blindly tested by OLA-Simple.

Rationale: Being ART-naive, none had received more than two regimens.

Answer: 0
"""

"""
Question: 4405 

Evidence: De-identified specimens from treatment-naive adults were blindly tested by OLA-Simple.

Rationale: All individuals had received zero regimens at sampling, so they received the same number of regimens.

Answer: Yes
"""

"""
Question: 4406 

Evidence: De-identified specimens from treatment-naive adults were blindly tested by OLA-Simple.

Rationale: As ART-naive, individuals had not yet received one regimen at sampling.

Answer: No
"""

"""
Question: 4501 

Evidence: De-identified specimens from treatment-naive adults were blindly tested by OLA-Simple.

Rationale: No individuals had initiated ART at sampling; hence none received dolutegravir.

Answer: 0
"""

"""
Question: 4502 

Evidence: De-identified specimens from treatment-naive adults were blindly tested by OLA-Simple.

Rationale: No individuals had initiated ART at sampling; hence none received darunavir.

Answer: 0
"""

"""
Question: 5101 

Evidence: Table 1. Genotyping results by OLA-Simple. Genotyping data by OLA-Simple and MiSeq are available in Supplementary Table 2 (https://links.lww.com/QAD/B693).

Rationale: The paper provides counts by codon across all samples but does not provide, in the main text, the number of unique individuals with one or more mutations; without the supplementary table, this cannot be determined.

Answer: NA
"""

"""
Question: 5102 

Evidence: Specifically, we have designed probes to detect major drug resistance mutations to NNRTIs (EFV/NVP) and NRTIs (3TC/TDF). In the context of HIV, we have designed ligation probes to detect mutations associated with resistance to other drug classes [e.g. integrase strand transfer inhibitors (unpublished) and protease inhibitors].

Rationale: The study did not test or report INSTI resistance mutations in participants; integrase-related work is noted as unpublished.

Answer: NA
"""

"""
Question: 5103 

Evidence: Universal probes for K65R in the OLA-Simple kit were slightly modified for the subtype B Mexican variants. Table 1 shows for K65R: TP = 1, TN = 53, FP = 0, FN = 0.

Rationale: K65R is a major TDF-resistance mutation; the results show one true-positive instance, indicating one individual with a TDF-resistance mutation.

Answer: 1
"""

"""
Question: 5104 

Evidence: In the context of HIV, we have designed ligation probes to detect mutations associated with resistance to other drug classes [e.g. integrase strand transfer inhibitors (unpublished) and protease inhibitors]. As new recommendations for first-line ART regimens are implemented globally, new formats of the OLA-Simple kit can be manufactured to detect relevant mutations associated with virologic failure of these ART.

Rationale: The study did not report any INSTI-resistance mutations in individuals; integrase-related detection is noted as unpublished/future work.

Answer: NA
"""

"""
Question: 6101 

Evidence: OLA- Simple detects the presence of specific drug-resistance mutations in a PCR amplified HIV template with nearly 100% specificity conveyed by enzyme-mediated ligation of labeled genotype-specific oligonucleotide probes to a common capture probe at the site of the mutation. Amino acid mutations were queried against the Stanford HIV Drug Resistance Database.

Rationale: The paper used a genotypic assay (OLA-Simple) and database interpretation; no phenotypic susceptibility test was used.

Answer: NA
"""

"""
Question: 6102 

Evidence: Amino acid mutations were queried against the Stanford HIV Drug Resistance Database. The OLA-Simple kit contains lyophilized reagents for easy assay setup, lateral flow strips for visual detection of HIVDR, and software guidance to enable first-time users to perform the assay with minimal training.

Rationale: No IC50/IC90 values are reported; the study is purely genotypic.

Answer: No
"""

"""
Question: 6103 

Evidence: Amino acid mutations were queried against the Stanford HIV Drug Resistance Database. The updated OLA-Simple assay clearly differentiated 0% (wild-type HIV) from 10% mutant across all codons.

Rationale: There are no IC50 fold-change measurements reported; only genotypic detection thresholds are discussed.

Answer: No
"""

"""
Question: 6104 

Evidence: OLA- Simple detects the presence of specific drug-resistance mutations in a PCR amplified HIV template with nearly 100% specificity conveyed by enzyme-mediated ligation of labeled genotype-specific oligonucleotide probes to a common capture probe at the site of the mutation. Ligation products were then visualized by lateral flow detection using gold particles.

Rationale: No phenotypic susceptibility assay was performed; the methodology is genotypic (OLA-Simple with lateral flow readout).

Answer: NA
"""

"""
Question: 6105 

Evidence: Amino acid mutations were queried against the Stanford HIV Drug Resistance Database. The accuracy of OLA-Simple genotyping results was estimated by comparison to MiSeq genotypes, excluding IND results.

Rationale: The paper does not measure or report replication capacity.

Answer: No
"""

"""
Question: 6106 

Evidence: OLA- Simple detects the presence of specific drug-resistance mutations in a PCR amplified HIV template with nearly 100% specificity conveyed by enzyme-mediated ligation of labeled genotype-specific oligonucleotide probes to a common capture probe at the site of the mutation. Ligation products were then visualized by lateral flow detection using gold particles.

Rationale: No phenotypic susceptibility testing of drugs was conducted; therefore no drugs were tested phenotypically.

Answer: NA
"""

"""
Question: 7101 

Evidence: DNA standards containing plasmid mixtures with 0%, 10%, 25%, and 100% of MUT target (n = 5 each) were genotyped by OLA-Simple. De-identified specimens from treatment-naive adults were blindly tested by OLA-Simple , and the results compared to results from MiSeq sequencing.

Rationale: The study used clinical specimens and plasmid standards for assay validation; it did not create site-directed mutant isolates as study isolates.

Answer: No
"""

"""
Question: 7102 

Evidence: Plasma specimens were extracted using the Qiagen QIAmp Viral RNA kit (Qiagen, Hilden, Germany) according to the manufacturer's instructions. Extracted RNA was reverse-transcribed in a rehydrated lyophilized reverse-transcription reaction.

Rationale: The study does not describe any in vitro passage or culture of isolates; it relies on direct plasma RNA and plasmid standards.

Answer: No
"""